JBM Healthcare reports strong 2025 results, board changes

JBM Healthcare (HKEX: 2161) reported robust annual results for the year ended March 31, 2025, highlighted by a 20.7% increase in revenue to HKD782.3 million and a 51.2% surge in profit attributable to equity shareholders, reaching HKD197.3 million. The Board is recommending a final dividend of HKD11.5 cents per share, bringing the total dividend for the year to HKD17.0 cents per share, significantly up from HKD7.5 cents per share in 2024. The company attributes this success to strong brand performance, effective marketing, and disciplined execution across its Branded Medicines, Proprietary Chinese Medicines, and Health & Wellness segments.